Herbs (Global Traditional) · European
Centaury (Centaurium erythraea) (Centaurium erythraea)
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Centaury (Centaurium erythraea) contains bitter compounds called secoiridoids, particularly gentiopicroside, which stimulate digestive secretions through bitter taste receptors. The European Medicines Agency recognizes its traditional use for mild dyspeptic symptoms including bloating and indigestion.
Centaury (Centaurium erythraea) is a medicinal herb native to Europe, Southwest Asia, and North Africa, belonging to the Gentianaceae family. The aerial parts (leaves, stems, and flowers) are harvested when in flower and dried for teas or extracts, or used fresh in infusions, liquid extracts, or tinctures.
No human clinical trials, RCTs, or meta-analyses have been conducted on centaury according to available sources. The European Medicines Agency recognizes its traditional use for digestive complaints based on 30+ years of documented use, but notes the complete absence of clinical studies.
No clinically studied dosage ranges exist due to lack of human trials. Traditional use involves dried herb as tea (infusion sipped slowly over weeks) or liquid extracts, with German Commission E approving it for dyspeptic complaints without specifying doses. Consult a healthcare provider before starting any new supplement.
Centaury (Centaurium erythraea) is not consumed as a food for macronutrient value but rather as a bitter herbal preparation; it has negligible caloric, protein, fat, and carbohydrate content when used in typical doses (1–4 g dried herb for tea or equivalent extract). **Key bioactive compounds:** • **Secoiridoid glycosides (bitter compounds):** Swertiamarin (~0.5–3% of dried herb), gentiopicroside (~0.1–1.5%), sweroside, and centapicrin — these are the primary pharmacologically active constituents responsible for bitter-taste-mediated digestive stimulation; swertiamarin is considered the dominant bitter principle. • **Xanthones:** Eustomin, decussatin, methylbellidifolin (~0.01–0.3% collectively); these exhibit antioxidant and anti-inflammatory properties in preclinical models. • **Phenolic acids:** Protocatechuic acid, sinapic acid, ferulic acid, and caffeic acid derivatives (trace to low concentrations). • **Flavonoids:** Small quantities of quercetin, kaempferol, and luteolin glycosides; concentrations vary with geographic origin but generally <0.5% of dried herb. • **Triterpenes and phytosterols:** Oleanolic acid, β-sitosterol, stigmasterol (trace amounts). • **Volatile compounds:** Minimal essential oil content (<0.1%); includes monoterpenes and small aldehydes contributing to aroma. • **Minerals:** Trace amounts of potassium, calcium, magnesium, iron, zinc, and manganese have been detected in aerial parts, but concentrations are too low to be nutritionally significant at typical dosing. • **Vitamins:** No meaningful vitamin content at therapeutic doses. **Bioavailability notes:** Secoiridoid glycosides are partially hydrolyzed in the gastrointestinal tract; swertiamarin's bitter-taste receptor (TAS2R) activation occurs locally in the oral cavity and GI tract, meaning systemic bioavailability is less relevant than local receptor interaction for digestive effects. Xanthones have relatively low oral bioavailability due to poor aqueous solubility but may exert local antioxidant effects in the GI lumen. Hot-water extraction (tea preparation) efficiently extracts secoiridoids and phenolics; hydroalcoholic tinctures (45–70% ethanol) yield broader extraction including xanthones. Compound concentrations vary significantly based on plant part (aerial parts vs. whole herb), harvest time (flowering stage yields highest secoiridoid content), geographic origin, and preparation method.
Centaury's secoiridoids, mainly gentiopicroside and sweroside, activate bitter taste receptors (TAS2Rs) on the tongue and digestive tract. This stimulates vagal pathways that increase gastric acid, bile, and pancreatic enzyme secretion. The bitter compounds may also directly stimulate gastrin release and enhance gastric motility through cholinergic pathways.
Clinical evidence for centaury is limited to traditional use documentation spanning over 30 years, which forms the basis for EMA HMPC recognition. No randomized controlled trials have been conducted in humans for digestive benefits. Preclinical studies in animal models suggest anti-inflammatory activity, but human efficacy data is lacking. The evidence relies primarily on historical traditional medicine use rather than modern clinical research.
Centaury is generally well-tolerated when used traditionally, with no serious adverse effects reported in the literature. Potential mild side effects may include gastric irritation in sensitive individuals due to bitter compound content. No significant drug interactions are documented, but theoretical interactions with acid-suppressing medications are possible. Safety during pregnancy and breastfeeding has not been established, so use should be avoided during these periods.
